Fifth Third Bancorp Announces Earnings Release Dates for 2026 and 2027
Fourth Quarter 2025 – Tuesday, January 20, 2026 – 10:00 AM ET
First Quarter 2026 – Friday, April 17, 2026 – 9:00 AM ET
Second Quarter 2026 – Friday, July 17, 2026 – 9:00 AM ET
Third Quarter 2026 – Monday, October 19, 2026 – 9:00 AM ET
Fourth Quarter 2026 – Tuesday, January 19, 2027 – 10:00 AM ET
First Quarter 2027 – Tuesday, April 20, 2027 – 9:00 AM ET
Second Quarter 2027 – Tuesday, July 20, 2027 – 9:00 AM ET
Third Quarter 2027 – Tuesday, October 19, 2027 – 9:00 AM ET
Financial results are expected to be available at approximately 6:30 AM ET on each of the dates listed above. Conference calls will be webcast live and may be accessed through the Fifth Third Investor Relations website at www.53.com (click on 'About Us' then 'Investor Relations'). Those unable to listen to the live webcasts may access a webcast replay through the Fifth Third Investor Relations website at the same web address.
About Fifth Third
Fifth Third is a bank that's as long on innovation as it is on history. Since 1858, we've been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it's one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people, and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere's World's Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation's highest performing regional bank, but to be the bank people most value and trust.
Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank and its common stock is traded on the NASDAQ® Global Select Market under the symbol 'FITB.' Investor information and press releases can be viewed at www.53.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
27 minutes ago
- Toronto Star
Top NAHREP Agent, Vivian Lesny, Joins eXp Realty to Champion Community, Culture, and Collaboration
BELLINGHAM, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) — eXp Realty®, 'the most agent-centric real estate brokerage on the planet™' and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced that top-producing Southern California agent and NAHREP Top 250 Latina leader, Vivian Lesny, has joined its growing global network. With more than two decades in real estate, Lesny surpassed $70 million in sales in 2024 and has closed more than 88 transactions in a single year, all while maintaining a consistent presence among NAHREP's Top 250 Latino Agents in the U.S. and Top 100 in the Southwest. A seasoned professional and native Culver City resident with deep roots in Marina Del Rey, Playa Vista, Playa del Rey and Westchester, Lesny is known not just for production, but for purpose. Her high-performing business, including a flipping portfolio that accounts for 35% of her income, is matched by her commitment to community and equity in homeownership.
Cision Canada
27 minutes ago
- Cision Canada
Crypto Treasury Revolution: How $47B Corporate Shift Creates New Investment Opportunities
Issued on behalf of CEA Industries, Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- Equity Insider News Commentary – The corporate crypto revolution has moved from experiment to mainstream strategy, as public companies poured $47.3 billion into digital assets in 2025 alone, significantly outpacing ETF inflows of $31.7 billion and signaling a fundamental shift in how businesses manage their treasuries. This institutional embrace has been accelerated by regulatory clarity, with pro-crypto policies and the passage of legislation like the CLARITY Act creating a pathway for traditional corporations to treat digital assets as legitimate reserve holdings. Leading research firm DWF Ventures published comprehensive analysis showing that 14 major public companies now collectively hold $76 billion in digital assets, with $40 billion deployed in just the past year alone. The momentum shows no signs of slowing, as over 60 public companies have now confirmed cryptocurrency positions on their balance sheets, spanning everything from tech giants to entertainment companies, and pointing the market towards innovative crypto-focused companies including CEA Industries, Inc. (NASDAQ: BNC), BIT Mining Limited (NYSE: BTCM), Upexi, Inc. (NASDAQ: UPXI), Bitcoin Depot Inc. (NASDAQ: BTM), and Canaan Inc. (NASDAQ: CAN). Mordor Intelligence forecasts the global cryptocurrency market will surge from $2.96 trillion in 2025 to $7.98 trillion by 2030, representing a robust 30.1% CAGR driven by institutional adoption and regulatory frameworks. Meanwhile, Grand View Research projects the cryptocurrency infrastructure market will expand from $5.70 billion in 2024 to $11.71 billion by 2030 at a 13.1% CAGR, reflecting the growing demand for institutional-grade crypto treasury solutions that these pioneering companies are racing to capture. CEA Industries, Inc. (NASDAQ: BNC) isn't your typical cryptocurrency story. While other companies scrambled to catch the Bitcoin wave or jumped on the latest trend, this Colorado-based firm made a calculated bet that could reshape how institutional investors think about digital assets. In August 2025, CEA Industries completed a massive $500 million private placement specifically earmarked for one purpose: building the world's largest corporate treasury of BNB tokens. The company immediately signaled its commitment by changing its ticker symbol from VAPE to BNC, reflecting its new identity as the premier publicly traded gateway to the BNB ecosystem. But what exactly is BNB? Think of it as the fuel that powers one of the world's busiest blockchain networks. BNB (originally called Binance Coin) is the native cryptocurrency of the BNB Chain ecosystem, which processes millions of transactions daily for everything from trading and payments to smart contracts and decentralized applications. Unlike Bitcoin, which primarily serves as digital gold, BNB has real-world utility baked into its design. Users can stake it to earn rewards, pay transaction fees at discounted rates, and participate in the growing decentralized finance (DeFi) ecosystem. Perhaps most importantly, BNB features a quarterly "auto-burn" mechanism that permanently removes tokens from circulation, creating built-in scarcity that could benefit long-term holders. Here's where CEA Industries gets interesting. The company didn't just raise money and hope for the best. They assembled what might be the most impressive crypto-focused management team on Wall Street. David Namdar, co-founder of Galaxy Digital (one of the largest crypto investment firms), stepped in as CEO. Russell Read, former Chief Investment Officer at CalPERS (managing over $400 billion in assets) and Deputy CIO of Deutsche Bank Asset Management, joined as CIO. The board welcomed Hans Thomas, founding partner of 10X Capital, the firm managing BNC's treasury strategy. This isn't a group of crypto newcomers making speculative bets. These are seasoned financial professionals who've managed billions of dollars and understand institutional-grade risk management. The results speak for themselves. In August 2025, BNC announced the purchase of 200,000 BNB tokens worth approximately $160 million, officially making it the largest corporate holder of BNB globally. This wasn't just a headline grab—it demonstrated the company's ability to execute on its strategy quickly and at scale. The timing appears strategic. While BNB consistently ranks among the top five cryptocurrencies by market capitalization, most U.S. investors still can't buy it directly through traditional brokerage accounts. CEA Industries recognized this gap and positioned itself as the solution, offering regulated, SEC-compliant access to BNB exposure without the complexity of crypto wallets or exchange accounts. The company's financial backing adds credibility to its mission. The $500 million raise attracted over 140 institutional and crypto-native investors, including Pantera Capital, Arche Capital, ExodusPoint Capital Management, and Cantor Fitzgerald & Co. served as lead financial advisor, bringing Wall Street expertise to the strategy. What sets BNC apart from other crypto treasury companies is its singular focus. While competitors diversify across multiple digital assets, CEA Industries made an all-in bet on BNB Chain's ecosystem growth. The company believes this focused approach will allow it to capture maximum value as institutional adoption accelerates. The potential upside follows historical patterns. When MicroStrategy adopted Bitcoin as its primary treasury asset in 2020, the stock gained nearly 2,000% at its peak. Similar treasury strategies by companies like Janover (Solana) and MetaPlanet (Bitcoin) produced dramatic stock price moves following their announcements. CEA Industries has positioned itself to potentially benefit from this same dynamic, but with an asset that powers one of the most active blockchain ecosystems on Earth. With plans to deploy the remaining treasury capital and potential access to an additional $750 million through warrant exercises, BNC appears built for the long game in an ecosystem that's just getting started. BIT Mining Limited (NYSE: BTCM) announced its strategic expansion into the Solana ecosystem on July 10, 2025, marking a significant shift from traditional Bitcoin mining to building a robust SOL treasury worth up to $300 million. "While we continue to make progress in our crypto mining operations, we have strategically shifted our focus to actively explore opportunities within the Solana ecosystem," remarked Mr. Xianfeng Yang, CEO of BIT Mining."This move reflects our commitment to capturing broader market potential and aligning with emerging trends that can drive long-term value and growth for the Company." The cryptocurrency mining company plans to raise between $200-300 million in phases to convert existing crypto holdings into SOL tokens while also operating validator nodes to support network decentralization and earn staking rewards. This strategic transformation positions BIT Mining to capture emerging opportunities in the rapidly growing Solana blockchain ecosystem, leveraging its existing infrastructure and technical expertise to create sustainable shareholder value. Upexi, Inc. (NASDAQ: UPXI) announced it surpassed 2 million SOL tokens in its treasury as of August 4, 2025, representing a massive 172% increase from 735,692 SOL at the end of June following a $200 million capital raise. "July was a game-changing month for Upexi, particularly with respect to accretive capital raises and a resulting drastic increase in our Solana treasury," said Allan Marshall, CEO of Upexi. "During the month, we raised over $200 million and grew our Solana holdings by over 172% to 2 million SOL. And we continued to generate additional value for shareholders via an estimated 8% staking yield and additional purchases of discounted locked Solana." The brand owner turned crypto treasury company now holds approximately $334 million worth of Solana tokens, with substantially all coins being staked to earn roughly 8% annual yield, generating about $65,000 per day in revenue. Upexi has positioned itself as a pure-play Solana investment vehicle for public market investors, trading at attractive valuations relative to its underlying SOL holdings while benefiting from built-in gains through purchasing locked SOL at discounted prices. Bitcoin Depot Inc. (NASDAQ: BTM) reported strong Q2 2025 financial results on August 12, 2025, with revenue growing 6% year-over-year to $172.1 million and net income surging 183% to $12.3 million driven by expanded kiosk deployment and higher transaction volumes. The leading Bitcoin ATM operator, which operates over 8,800 kiosk locations across 47 states, significantly improved profitability with Adjusted EBITDA jumping 46% to $18.5 million while strengthening its balance sheet to nearly $60 million in cash and digital assets. "With nearly $60 million in cash and digital assets, we are well-positioned to capitalize on growth opportunities, both in the U.S. and internationally," said Brandon Mintz, Founder and CEO of Bitcoin Depot. "Looking ahead, we remain focused on scaling efficiently and delivering sustained value for our customers and shareholders." Bitcoin Depot also strategically added to its Bitcoin treasury holdings, bringing total Bitcoin reserves to 100.35 BTC, while simplifying its corporate structure and providing guidance for continued high-single-digit revenue growth in Q3 2025. Canaan Inc. (NASDAQ: CAN) reported July 2025 production results showing the Bitcoin mining company mined 89 bitcoins during the month while increasing its total Bitcoin holdings to 1,511 BTC as part of its newly adopted cryptocurrency holding policy. "We're pleased to report quarter-over-quarter improvement in our bitcoin mining performance, with monthly production resulting in 89 bitcoins, driven by a stronger bitcoin price and lower average power costs," said Nangeng Zhang, Chairman and CEO of Canaan. "In line with our recently announced Cryptocurrency Holding Policy, we retain bitcoins acquired through our daily operations as a long-term reserve asset. This policy allows us to accumulate bitcoin, and our total holdings at month-end were 1,511 bitcoins." The mining hardware manufacturer and operator faced some operational challenges with deployed hashrate declining to 7.95 EH/s and operating hashrate at 6.24 EH/s, primarily due to planned exits from underperforming hosting sites in favor of better-performing partners. Canaan continues to strengthen its position in the mining industry with recent major orders from public mining companies like Cipher Mining and CleanSpark, while maintaining operations across multiple regions including America, Kazakhstan, and other international locations. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Equity Insider on behalf of Market IQ Media Group Inc. ("MIQ"). MIQ has been paid a fee for CEA Industries Inc. advertising and digital media from Creative Digital Media Group ("CDMG"). There may be 3rd parties who may have shares of CEA Industries Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of CEA Industries Inc. but reserve the right to buy and sell, and will buy and sell shares of CEA Industries Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved on behalf of CEA Industries Inc. by CDMG; this is a paid advertisement, we currently own shares of CEA Industries Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
27 minutes ago
- Cision Canada
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Fate Therapeutics, Inc. (NASDAQ: FATE), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Nektar Therapeutics (NASDAQ: NKTR). Global Market Insights estimates the global oncology market at US$345.1 billion in 2025 and forecasts it will climb to US$866.1 billion by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute $377.1 billion to that total. Vision Research Reports projects an even larger figure for the global cancer drug sector, predicting it will surpass US$900 billion in sales by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep. In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025. For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types. "We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year," said Jared Kelly, CEO of Oncolytics. "As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors." The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically "cold" tumors—those typically invisible to the immune system—into "hot" tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone. Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication. Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution. Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners. The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population. Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment. With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC. The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets. In other recent industry developments and happenings in the market include: Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported strong Q2 2025 results with $60 million in total product revenue, driven primarily by its breakthrough melanoma therapy Amtagvi, which treated over 100 patients in the second quarter. "Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients," said Frederick Vogt, Ph.D., J.D., Interim President and CEO of Iovance. "We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs." The company's tumor-infiltrating lymphocyte (TIL) therapy—which uses a patient's own immune cells to fight cancer—generated $54.1 million in revenue and represents the first FDA -approved T-cell therapy for solid tumors, offering new hope for advanced melanoma patients who have tried other treatments without success. With expanded clinical trials planned for lung cancer and endometrial cancer, plus international approvals expected in Canada and other markets, Iovance is positioned to bring its innovative cancer treatment to patients worldwide. Fate Therapeutics, Inc. (NASDAQ: FATE) recently announced promising clinical progress for its off-the-shelf CAR T-cell therapy FT819, which showed lasting responses in lupus patients and received FDA clearance to begin trials for a solid tumor program targeting MICA/B proteins. While primarily focused on autoimmune diseases, the company's next-generation FT836 CAR T-cell therapy represents a significant advancement in cancer treatment as it's designed to target solid tumors without requiring harsh conditioning chemotherapy, potentially making the treatment safer and more accessible. "Building on this momentum, we are also working closely with the FDA under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026," said Bob Valamehr, Ph.D., MBA, President and CEO of Fate Therapeutics. "Additionally, we continue to strengthen our broader pipeline programs with an extended partnership with Ono Pharmaceuticals, and advancements in bringing our next-generation, off-the-shelf CAR T cells with Sword and Shield™ technology toward the clinic." The company's stem cell-based platform continues to advance multiple programs, including partnerships for HER2-positive solid tumors, positioning Fate as a leader in developing ready-made cancer cell therapies. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) remains on track to submit its application for INO-3107 in the second half of 2025, targeting Recurrent Respiratory Papillomatosis (RRP), a rare cancer-related condition caused by HPV that affects the airways. The company's DNA medicine platform represents a novel approach to treating HPV-related diseases and cancers, with INO-3107 showing significant clinical benefit by reducing the need for repeated surgeries in RRP patients from an average of 4.1 procedures annually to just 0.9 procedures. "We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis (RRP) patients and their physicians—a treatment option with the potential to change the trajectory of this disease," said Dr. Jacqueline Shea, President and CEO of INOVIO. "I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026." Beyond RRP, Inovio's technology platform is designed to treat various HPV-related cancers and other tumors by teaching the body's immune system to recognize and fight cancer cells. With breakthrough therapy designation from the FDA and plans for a trial involving 100 patients, INO-3107 could become the first DNA-based therapy approved for treating this serious cancer-related condition. Nektar Therapeutics (NASDAQ: NKTR) reported impressive Phase 2b data for rezpegaldesleukin in treating moderate to severe atopic dermatitis, with the company positioning this immune system regulator as a first-in-class treatment for autoimmune diseases. While primarily focused on autoimmune conditions, Nektar's pipeline includes NKTR-255, a treatment designed to boost the immune system's ability to fight cancer, which is being tested in multiple ongoing clinical trials with various partners. "As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders," said Howard W. Robin, President and CEO of Nektar. "Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target." The company's technology platform creates novel treatments that could potentially address both autoimmune diseases and cancer by enhancing the immune system's cancer-fighting abilities. With additional data expected from hair loss trials in December 2025 and continued development of next-generation programs, Nektar is advancing a unique approach to immune system therapy that could benefit millions of patients with serious diseases. CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
